LM-305 |
LM-305 |
Phase 2 Clinical |
LaNova Medicines Ltd |
Multiple Myeloma |
Details
|
Anti-GPRC5D CAR-T Cells Therapy (Shanghai YaKe Biotechnology) |
|
Phase 2 Clinical |
Shanghai YaKe Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
IBI-3003 |
IBI3003; IBI-3003 |
Phase 2 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Multiple Myeloma |
Details
|
BCMA-GPRC5D CAR-T Cells Therapy(Wuhan Union Hospital) |
|
Phase 2 Clinical |
Guangzhou Bio-Gene Technology Co Ltd, Wuhan Union Hospital |
Multiple Myeloma |
Details
|
MBS-314 |
MBS-314 |
Phase 2 Clinical |
Beijing Mabworks Biotech Co Ltd |
Multiple Myeloma |
Details
|
CT-071 |
CT071; CT-071 |
Phase 2 Clinical |
CARsgen Therapeutics Holdings Ltd |
Leukemia, Plasma Cell; Multiple Myeloma |
Details
|
Anti-GPRC5D CAR-T Cells Therapy(920th Hospital) |
|
Phase 2 Clinical |
The 920th Hospital Of Joint Logistics Support Force Of PLA |
Multiple Myeloma |
Details
|
Ori-CAR-017 |
Ori-CAR-017; OriCAR-017; GPRC5D-CAR-T |
Phase 2 Clinical |
OriCell Therapeutics Co Ltd |
Hematologic Diseases; Hemorrhagic Disorders; Immunoproliferative Disorders; Hemostatic Disorders; Paraproteinemias; Neoplasms; Blood Protein Disorders; Multiple Myeloma; Immune System Diseases; Vascular Diseases; Neoplasms, Plasma Cell; Cardiovascular Diseases; Lymphoproliferative Disorders |
Details
|
LBL-034 |
LBL-034 |
Phase 2 Clinical |
Nanjing Leads Biolabs Co Ltd |
Neoplasms; Multiple Myeloma |
Details
|
CC-95266 |
CC-95266; BMS986393; BMS-986393 |
Phase 2 Clinical |
Juno Therapeutics Inc |
Multiple Myeloma |
Details
|
BCMAxGPRC5D CAR-T therapy (Juno Therapeutics) |
BMS-986453 |
Phase 1 Clinical |
Juno Therapeutics Inc |
Multiple Myeloma |
Details
|
SIM-0500 |
SIM-0500; SIM0500 |
Phase 1 Clinical |
Hainan Xiansheng Re Ming Pharmaceutical Co Ltd |
Bone Marrow Neoplasms; Multiple Myeloma |
Details
|
OriC-321 |
OriC-321; Ori-C-321 |
Phase 1 Clinical |
Zhejiang University, OriCell Therapeutics Co Ltd |
Multiple Myeloma |
Details
|
CAR-GPRC5D |
CAR-GPRC5D |
Phase 1 Clinical |
Nanjing Iaso Biotherapeutics Co Ltd |
Leukemia, Plasma Cell; Multiple Myeloma |
Details
|
Forimtamig |
RG-6234 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Multiple Myeloma |
Details
|
MCARH-109 |
|
Phase 1 Clinical |
Memorial Sloan Kettering Cancer Center, Juno Therapeutics Inc, Eureka Therapeutics Inc |
Multiple Myeloma |
Details
|
RO-7425781 |
RO-7425781 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Multiple Myeloma |
Details
|
Anti-GPRC5D-CD19-CAR-T cell therapy(The Second People Hospital Of Guangdong Province) |
|
|
The Second People Hospital Of Guangdong Province |
|
Details
|
Anti-GPRC5D CAR-T Cells Therapy(Institute of Hematology & Blood Diseases Hospital) |
|
|
Institute Of Hematology & Blood Diseases Hospital |
|
Details
|
LM-305 |
LM-305 |
Phase 2 Clinical |
LaNova Medicines Ltd |
Multiple Myeloma |
Details
|
Anti-GPRC5D CAR-T Cells Therapy (Shanghai YaKe Biotechnology) |
|
Phase 2 Clinical |
Shanghai YaKe Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
IBI-3003 |
IBI3003; IBI-3003 |
Phase 2 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Multiple Myeloma |
Details
|
BCMA-GPRC5D CAR-T Cells Therapy(Wuhan Union Hospital) |
|
Phase 2 Clinical |
Guangzhou Bio-Gene Technology Co Ltd, Wuhan Union Hospital |
Multiple Myeloma |
Details
|
MBS-314 |
MBS-314 |
Phase 2 Clinical |
Beijing Mabworks Biotech Co Ltd |
Multiple Myeloma |
Details
|
CT-071 |
CT071; CT-071 |
Phase 2 Clinical |
CARsgen Therapeutics Holdings Ltd |
Leukemia, Plasma Cell; Multiple Myeloma |
Details
|
Anti-GPRC5D CAR-T Cells Therapy(920th Hospital) |
|
Phase 2 Clinical |
The 920th Hospital Of Joint Logistics Support Force Of PLA |
Multiple Myeloma |
Details
|
Ori-CAR-017 |
Ori-CAR-017; OriCAR-017; GPRC5D-CAR-T |
Phase 2 Clinical |
OriCell Therapeutics Co Ltd |
Hematologic Diseases; Hemorrhagic Disorders; Immunoproliferative Disorders; Hemostatic Disorders; Paraproteinemias; Neoplasms; Blood Protein Disorders; Multiple Myeloma; Immune System Diseases; Vascular Diseases; Neoplasms, Plasma Cell; Cardiovascular Diseases; Lymphoproliferative Disorders |
Details
|
LBL-034 |
LBL-034 |
Phase 2 Clinical |
Nanjing Leads Biolabs Co Ltd |
Neoplasms; Multiple Myeloma |
Details
|
CC-95266 |
CC-95266; BMS986393; BMS-986393 |
Phase 2 Clinical |
Juno Therapeutics Inc |
Multiple Myeloma |
Details
|
BCMAxGPRC5D CAR-T therapy (Juno Therapeutics) |
BMS-986453 |
Phase 1 Clinical |
Juno Therapeutics Inc |
Multiple Myeloma |
Details
|
SIM-0500 |
SIM-0500; SIM0500 |
Phase 1 Clinical |
Hainan Xiansheng Re Ming Pharmaceutical Co Ltd |
Bone Marrow Neoplasms; Multiple Myeloma |
Details
|
OriC-321 |
OriC-321; Ori-C-321 |
Phase 1 Clinical |
Zhejiang University, OriCell Therapeutics Co Ltd |
Multiple Myeloma |
Details
|
CAR-GPRC5D |
CAR-GPRC5D |
Phase 1 Clinical |
Nanjing Iaso Biotherapeutics Co Ltd |
Leukemia, Plasma Cell; Multiple Myeloma |
Details
|
Forimtamig |
RG-6234 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Multiple Myeloma |
Details
|
MCARH-109 |
|
Phase 1 Clinical |
Memorial Sloan Kettering Cancer Center, Juno Therapeutics Inc, Eureka Therapeutics Inc |
Multiple Myeloma |
Details
|
RO-7425781 |
RO-7425781 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Multiple Myeloma |
Details
|
Anti-GPRC5D-CD19-CAR-T cell therapy(The Second People Hospital Of Guangdong Province) |
|
|
The Second People Hospital Of Guangdong Province |
|
Details
|
Anti-GPRC5D CAR-T Cells Therapy(Institute of Hematology & Blood Diseases Hospital) |
|
|
Institute Of Hematology & Blood Diseases Hospital |
|
Details
|